TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05365815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melanated Group Midwifery Care
Description: Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
Study: NCT05102071

Intervention type: DRUG
Intervention: empagliflozin
Description: empagliflozin

Intervention type: DRUG
Intervention: metformin
Description: metformin

Intervention type: DRUG
Intervention: metformin
Description: metformin

Intervention type: DRUG
Intervention: sulfonylurea
Description: sulfonylurea
Study: NCT04810910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: iNeo-Vac-P01 (peptides)： 300 mcg per peptide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF: 40 mcg
Study: NCT06162468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel
Description: EUS-PCA using gemcitabine and paclitaxel
Study: NCT06504732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
Study: NCT06031272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS-J
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS-J
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 3BNC117-LS-J
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 10-1074-LS-J
Description: Administered by intravenous (IV) infusion
Study: NCT06489548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foralumab TZLS-401 50 µg
Description: Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foralumab TZLS-401 100 µg
Description: Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
Study: NCT05650710

Intervention type: DEVICE
Group type: OTHER
Intervention: Nerve stimulation using nerve stimulation device and sterile wire electrode.
Description: A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
Study: NCT06523803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW171
Description: Administered per protocol requirements
Study: NCT06123338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered on an every 3-week dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered on an every 3-week dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin every 3 weeks, +/-7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
Study: NCT05875961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose A/H2N3c + standard dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intermediate dose A/H2N3c + standard dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose A/H2N3c + standard dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose A/H2N3c non-adjuvanted
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lowest dose A/H2N3c + high dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose A/H2N3c + high dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Study: NCT06506604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLEVER
Description: CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLEVER
Description: CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLEVER
Description: CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLEVER
Description: CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes.
Study: NCT05017662

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
Study: NCT06316843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir celecoxib dose 1
Description: 1500 mg valacyclovir 200 mg celecoxib taken two times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir celecoxib dose 2
Description: 750 mg valacyclovir 200 celecoxib mg taken two times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules colored matched to investigational product taken two times a day
Study: NCT06202053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of surgical incision
Description: The experimental group (patients received periareolar incision):~An arc-shaped incision was made on the lateral side of the patient's affected areola. The subcutaneous tissue was then dissociated between the lateral mammary gland and the skin to the level of the fourth intercostal space in front of the midaxillary line. The fatty tissue behind the breast was separated horizontally to expose the serratus anterior muscle, and an intercostal incision was made. The skin was pulled back throughout the procedure to expose a better surgical field and avoid damage to the mammary gland.~The control group (patients underwent an axillary incision):~For patients in the control group, an incision was made into the fourth intercostal space in the midline of the axilla, where subcutaneous tissue was separated and entered the chest.
Study: NCT06470100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
Study: NCT06635447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg, oral, twice daily; 4 days on and 3 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg, oral, twice daily; 4 days on and 3 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IV
Study: NCT05935059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tianeptine
Description: Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
Study: NCT05273749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablet, 5.6 mg
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT06091020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT05421325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN SSI
Description: Site-Specific Immunomodulator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal Saline
Study: NCT05876858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-butanol
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
Study: NCT05909111

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MRI weekly during the radiation treatment course (5 RMI added to the standard care)
Study: NCT05081713

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: high-intensity training focused on stepping in variable contexts
Description: Approximately 10 weeks (\~30 sessions) of high-intensity training

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: high-intensity training focused on stepping in variable contexts
Description: Approximately 10 weeks (\~30 sessions) of high-intensity training
Study: NCT04710576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
Study: NCT06474182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Treatment by Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Treatment by Apixaban
Study: NCT04618016

Intervention type: DEVICE
Intervention: UHMWPE with Vitamin E
Description: e.motion Pro (PS and UC) with MXE gliding surface

Intervention type: DEVICE
Intervention: UHMWPE without Vitamin E
Description: e.motion Pro (PS and UC) with β-PE gliding surface
Study: NCT05515367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desidustat
Description: Oral tablet
Study: NCT06258889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reward-focused intervention
Description: Participants complete three interventions based on the Positive Affect Treatment:~* Finding the silver lining includes attending to and appreciating positive aspects of past events~* Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~* Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive flexibility intervention
Description: This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure
Description: All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure
Description: All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
Study: NCT06488469

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological Interventions for children and adolescents
Description: Psychological Interventions for children and adolescents:~* Behavioral modifications using Functional Analysis and Parent Management Techniques~* Illness Management behavior - Motivational Interviewing, Cognitive Therapy to identify thinking errors posing challenges to self-management, Behavioral Modification to enhance self-management of illness, Solution focused therapy to manage identified barriers in illness -management~* Managing emotional problems- Cognitive Behavioral Therapy techniques~Psychological Interventions for Parents/ Caregivers:~* Parent management techniques- Identification of problem behaviors/deficit~* Education on Dysfunctional attitude and their effects Psycho-education for Children could be delivered best in Combined with Health Education and Nutritional education leading to dietary modifications.~* Individualized Treatment targets and Resetting targets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Interventions for children and adolescents
Description: Psychological Interventions for children and adolescents:~* Behavioral modifications using Functional Analysis and Parent Management Techniques~* Illness Management behavior - Motivational Interviewing, Cognitive Therapy to identify thinking errors posing challenges to self-management, Behavioral Modification to enhance self-management of illness, Solution focused therapy to manage identified barriers in illness -management~* Managing emotional problems- Cognitive Behavioral Therapy techniques~Psychological Interventions for Parents/ Caregivers:~* Parent management techniques- Identification of problem behaviors/deficit~* Education on Dysfunctional attitude and their effects Psycho-education for Children could be delivered best in Combined with Health Education and Nutritional education leading to dietary modifications.~* Individualized Treatment targets and Resetting targets
Study: NCT06449209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL1)
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL1)
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 1 (DL1)
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 2 (DL2)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 2 (DL2)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327 Dose Level 2 (DL2)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: IV infusion or oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: IV infusion or oral capsules
Study: NCT06515574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: developmental care
Description: Individualized Developmental Care that includes the light, noise, sleep, etc.
Study: NCT06298552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Intravenous infusion of placebo
Study: NCT05573945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Education and Active Listening
Description: Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Education
Description: Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
Study: NCT04424745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)
Description: Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.